March 2016 is here and the first quarter release of WHODrug has been distributed. The latest news and developments mentioned in the March newsletter edition are:

- The B3- and C3-formats coming in 2017
- New guide for CDISC SDTM compliance
- Upcoming release of WHODrug™ Insight
- New substances in WHODrug
- and more.

**Important Changes in WHODrug Formats in 2017**

In March 2017 UMC will introduce two new formats: the B3- and C3-formats with the intention to improve the structure of WHODrug products for better and more efficient review, analysis and reporting of multi-ingredient drugs. Test files for both formats are now accessible in the download area and the implementation guide with description of the new format can be found [here](#). The old B2- and C-formats will be available in parallel (in somewhat restricted versions) until December 2018.

**New Guide for CDISC SDTM compliance**

Get UMC assistance for compliance with the CM domain in the CDISC SDTM standard by using the newly released technical guide for industry. The guide is available on the [User Group Portal](#).

**New Functionality in WHODrug Change Analysis Tool (CAT)**

As a help to predict the workload involved, the Change Analysis Tool has been updated with the possibility to perform impact assessment for upgrading to the new B3- and C3-formats. CAT can now analyze uploaded data and deliver a summarised impact of the number of modified and deleted terms that will occur due to the when moving to the B3-format.

**Upcoming Release of WHODrug™ Insight**

WHODrug™ Insight is a completely new tool for analysing data available in the WHODrug™ product portfolio. WHODrug™ Insight will be released April 15, 2016. For Worldwide Corporate License holders, WHODrug™ Insight will be made available already March 1, 2016. More information about WHODrug™ Insight as well as information regarding upcoming Webinar training sessions will be communicated during spring 2016.

**Webinars Continues in 2016**

Monthly webinars will continue in 2016 given informative news regarding UMC products and services and discussing coding conventions - they are tailored for the end users. On the first Tuesday of each month two webinar sessions will take place at 9AM and 5PM Central European Time (CET). They are free of charge and open to all subscribers of the WHODrug. All past webinars are available on the User Group Portal – log in and take part of them.

**Upcoming webinar**

**Topic: Introduction to WHODrug Insight**

**Date:** Tuesday April 12 and April 26, 2016

**Time:** 9AM and 5PM Central European Time (CET)

Register for the webinar on the [User Group Portal](#)
Register Now For the 2016 WHODrug User Group Meetings

Take the opportunity to know about the latest WHODrug developments and to interact and share experiences with colleagues around the world – register now the 2016 WHODrug User Group Meetings:
- Hamburg, Germany – April 4, 2016
- Philadelphia, PA, USA – July 1, 2016
- TBA, Japan – November (Registration not yet open)

Attending the WHODrug User Group Meetings is free of charge if you work for an organisation with a valid WHODrug license. More information about on how to register is available on the User Group Portal

WHODrug Updated with New Substances

WHODrug is updated with new substances on a regular basis. In the March 1, 2016 release of WHODrug Enhanced, a new batch of substances from the U.S. FDA Substance Registration System (SRS) has been included. As for all entries available in the WHODrug, each new substance name is assigned with at least one ATC code.

SDG – New developments 2016

Are you creating lists of medicines of interests for your organization? Or see a need for creating such lists? Please, check out our Standardised Drug Groupings (SDGs)! The SDGs are an unbiased search strategy for creating lists of medicines of interest, maintained and continuously updated by the UMC.

For the March 2016 release of WHODrug there are three new SDGs developed:
- Drugs interacting with BCRP
- Antihistamines
- Benzodiazepines.

Buckle Up for the 4th Biennial Uppsala Forum Conference

“Pharmacovigilance’s role in rapid access to safer drugs” provides an international forum to discuss the challenge of balancing the need for rapid access to new drugs with the need to avoid exposing patients to unnecessary risks.

The conference is the premier venue for both cutting-edge research and for making findings useable in practice. Uppsala Forum’s agenda has two focus areas: research and practice/policy. Integrating these two areas provides opportunities for exchange on how to use evidence to increase drug safety in many settings, identify new relevant research questions, and develop new collaborations across sectors.
Did You Know?
That UMC continuously monitors New Drug Approvals from major regulatory authorities world-wide (such as EMA and U.S. FDA) to make sure that the latest drug names are expeditiously included in WHODrug.